Medicure (CVE:MPH) Shares Climb 3.5% – Still a Buy?

Shares of Medicure Inc. (CVE:MPH – Get Free Report) were up 3.5% during trading on Friday. The company traded as high as C$4.00 and last traded at C$3.83. Approximately 23,050 shares traded hands during mid-day trading, an increase of 394% from the average session volume of 4,670 shares. The stock had previously closed at C$3.70.

Medicure Price Performance

The company has a debt-to-equity ratio of 8.32, a quick ratio of 1.28 and a current ratio of 0.89. The stock’s 50 day simple moving average is C$3.51 and its two-hundred day simple moving average is C$1.82. The firm has a market capitalization of C$39.97 million, a PE ratio of -5.32 and a beta of 1.02.

About Medicure

(Get Free Report)

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.

Further Reading

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.